CATXHealthcare · Medical DevicesThe 16 Wall Street analysts covering Perspective Therapeutics, Inc. hold a median 12-month price target of $12 — +908.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Perspective Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (71): Smaller than most of the companies we track.
Value (16): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CATX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +908.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Oct 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 7 Oct 2026 | BTIG | Reiterates | Buy | — |
| 18 Sept 2026 | William Blair | Initiates | Outperform | — |
| 15 Sept 2026 | Wedbush | Reiterates | Outperform | — |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | — |
| 14 Aug 2026 | B of A Securities | Maintains | Neutral | — |
| 11 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 5 May 2026 | BTIG | Reiterates | Buy | — |
| 5 May 2026 | Wedbush | Reiterates | Outperform | — |
| 20 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 23 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 18 Mar 2026 | UBS | Maintains | Buy | — |
| 18 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 17 Mar 2026 | BTIG | Reiterates | Buy | — |
| 17 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 19 Feb 2026 | Piper Sandler | Initiates | Overweight | — |
| 30 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Jan 2026 | Wedbush | Reiterates | Outperform | — |
| 13 Jan 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CATX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Perspective Therapeutics, Inc. returned −56.8% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 2% of US stocks
Cheaper than 84% of US stocks
Cheaper than 58% of US stocks
Higher than 3% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Perspective Therapeutics, Inc. has a market value of $131.3M and an enterprise value of −$101.6M.
Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 72.1% year on year.
Net income over the same four quarters: −$116.4M.
Free cash flow in the twelve months to 30 June 2026: −$121.2M.
Trailing P/E: −0.8×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Perspective Therapeutics, Inc. employs 163 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Perspective Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Perspective Therapeutics reported updated VMT-α-NET clinical data at the European Society for Medical Oncology Congress 2026, including tumor responses, an 18-month progression-free survival rate of 72% across three cohorts, and no dose-limiting toxicities to date.
Why it matters — The update provides CATX watchers with interim efficacy and safety findings from the VMT-α-NET study.
Perspective Therapeutics announced interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors. The results are being presented in a rapid oral presentation at the ESMO Congress 2026.
Why it matters — The update provides CATX watchers with interim information about the safety and antitumor activity of a candidate in the company’s clinical pipeline.
Perspective Therapeutics said the FDA granted Fast Track Designation for development of [212Pb]PSV359 in adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.
Why it matters — The designation is a regulatory development for CATX’s PSV359 program in this patient population.
Perspective Therapeutics announced that data from its [²¹²Pb]VMT-α-NET program were accepted for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium, scheduled for November 5–7, 2026, in Las Vegas.
Why it matters — The acceptance places data from CATX’s [²¹²Pb]VMT-α-NET program on the agenda for a 2026 medical symposium.
Perspective Therapeutics announced that data from its lapemelanotide zapixetar ([212Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, scheduled for November 4-8, 2026, in Phoenix, Arizona. SITC plans to release further abstract details on November 3, 2026.
Why it matters — A CATX watcher would care because acceptance of the company's radiopharmaceutical data at a major cancer immunotherapy conference signals growing recognition of its pipeline progress and provides an upcoming opportunity to see clinical results.
The 16 Wall Street analysts covering Perspective Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $4 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Perspective Therapeutics, Inc., 14 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perspective Therapeutics, Inc. 22 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Perspective Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +908.8% from the last close, and Ticker Nerd's factor model ranks Perspective Therapeutics, Inc. 22 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Perspective Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CATX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $15 over the next 12 months.
Perspective Therapeutics, Inc. returned -56.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer.
The most recent item we track (MarketBeat, 23 Oct 2026): "Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update". Perspective Therapeutics reported updated VMT-α-NET clinical data at the European Society for Medical Oncology Congress 2026, including tumor responses, an 18-month progression-free survival rate of 72% across three cohorts, and no dose-limiting toxicities to date.
Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.
CEO Mr. Johan M. Spoor · 163 employees · United States · https://www.perspectivetherapeutics.com
